New Samsung Biosimilar Results Bode Well For Portfolio
This article was originally published in PharmAsia News
Executive Summary
With its first biosimilar product set to be launched by the end of this year, Samsung Bioepis has presented new long-term results from Phase III trials for several of its autoimmune disease biosimilars that show comparable safety and efficacy to the original products.